0
Observation |

A Case of Refractory Sézary Syndrome With Large-Cell Transformation Responsive to Brentuximab Vedotin

Kristen Corey, BS1; Deborah Cook, MD2; Jessica Bekker, MD2; Emiliano Mugnaini, MD, PhD3; Julie H. Lin, MD4
[+] Author Affiliations
1University of Massachusetts Medical School, Worcester
2Department of Pathology, University of Vermont College of Medicine, Burlington
3Division of Hematology/Oncology, University of Vermont College of Medicine, Burlington
4Division of Dermatology, University of Vermont College of Medicine, Burlington
JAMA Dermatol. 2014;150(2):210-212. doi:10.1001/jamadermatol.2013.5741.
Text Size: A A A
Published online

Extract

Brentuximab vedotin is a CD30-directed antibody/drug conjugate recently approved for the treatment of relapsed Hodgkin lymphoma (HL) and systemic anaplastic large-cell lymphoma (ALCL). Given that CD30 is variably expressed in mycosis fungoides (MF) and Sézary syndrome (SS), brentuximab vedotin is a promising treatment option for these cutaneous neoplasms. Initial studies have confirmed its clinical activity in refractory cases.

Article InformationCorresponding Author: Julie H. Lin, MD, Division of Dermatology, University of Vermont College of Medicine, 111 Colchester Ave, Burlington, VT 05401 (Julie.Lin@vtmednet.org).

Published Online: December 18, 2013. doi:10.1001/jamadermatol.2013.5741.

Conflict of Interest Disclosures: None reported.

Additional Contributions: We would like to thank Laura McGevna, MD, of the Division of Dermatology, and Paul Larson, NP, and Barbara Grant, MD, of the Division of Hematology/Oncology at University of Vermont College of Medicine for their help and expertise in caring for our patient. We would also like to thank the patient and her family for allowing us to publish this information.

Figures in this Article

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
/>
First page PDF preview

Figures

Place holder to copy figure label and caption
Figure 1.
Clinical Images of the Patient

A, Photograph of the patient at initial presentation. B, Rapid progression seen 6 months later despite multiple therapies. C, Rapid clearance of tumors and improvement of pruritus 10 months later after 5 treatment cycles of brentuximab vedotin.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Pathologic and Immunohistochemical Specimens

A, Skin biopsy specimen taken at initial presentation shows dense bandlike infiltrate of atypical lymphocytes (hematoxylin-eosin, original magnification ×10). B, Higher magnification (original magnification ×40) shows large cells with atypia (hematoxylin-eosin). Immunohistochemical staining shows CD30 positivity (original magnification ×40).

Graphic Jump Location

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
Jobs
brightcove.createExperiences();